Project backed by £9.1m funding from ARIA, the Advanced Research + Invention Agency, to develop synthetic chloroplast genomes Project is led by the Max-Planck Institute of Molecular Plant Physiology ...
Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB) are surging Monday after the biotech company shared an important regulatory update about one of its therapy treatments. What To Know: Spruce ...
Spruce Biosciences shares reached a 52-week high after a drug update and favorable comments on X by Martin Shkreli. Spruce said the Food and Drug Administration granted Breakthrough Therapy ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological ...
Spruce Biosciences Inc. (NASDAQ:SPRB) jumped to $175.00 during after-hours trading on Monday, up 34.20% or $44.60 from its closing price. Check out the current price of SPRB stock here. During regular ...
Centuries-old trees can hold clues about global weather patterns. A new UA study unlocked some of those clues.
Dec 10 (Reuters) - Spruce Biosciences (SPRB.O), opens new tab said on Tuesday it will wind down investments for its genetic disorder drug after it failed in a mid-stage trial, sending its shares down ...
A construction worker uses a lift while setting joists at Serán BioScience’s new medical warehouse in Bend. A bioscience business that develops and makes medications for pharmaceutical companies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback